Last Updated : February 3, 2025
Details
Generic Name:
guselkumab
Project Status:
Received
Therapeutic Area:
Crohn’s disease
Manufacturer:
Janssen Inc.
Call for patient/clinician input open:
Brand Name:
Tremfya
Project Line:
Reimbursement Review
Project Number:
SR0882-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with moderately to severely active Crohn’s disease.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
The treatment of adult patients with moderately to severely active Crohn’s disease.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Call for patient/clinician input open | December 13, 2024 |
---|---|
Call for patient/clinician input closed | February 18, 2025 |
Submission received | January 31, 2025 |
Submission accepted | - |
Last Updated : February 3, 2025